NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])

NCT03139513

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Melanoma

Interventions: Cobimetinib, Vemurafenib

Countries: France

This is a multicentre, ambispective (both retrospective and prospective), and non-interventional study conducted in France in adult participants with BRAF V600 mutation-positive unresectable or metastatic melanoma treated with cobimetinib in combination with vemurafenib (Zelboraf®).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Participants included in the TAU from 26 February 2015
* Participants with BRAF V600 mutation-positive unresectable or metastatic melanoma treated with cobimetinib in combination with vemurafenib
* For alive participants: participants who have been informed verbally and in writing about this study who do not object to their data being electronically processed or subjected to data quality control
* For participants who died before the inclusion period: participants who did not express their opposition when they were alive

Exclusion Criteria:

\- Alive participants unable to give informed consent

Locations (33)

Albi, France
Antony, France
Bayonne, France
Besançon, France
Bobigny, France
Bourg-en-Bresse, France
Chambéry, France
Clermont-Ferrand, France
Colmar, France
Dijon, France
Dijon, France
Le Mans, France
Lille, France
Limoges, France
Marseille, France
Montivilliers, France
Montpellier, France
Mulhouse, France
Nice, France
Paris, France
Paris, France
Pringy, France
Rennes, France
Rouen, France
Saint-Etienne, France
Saint-Germain, France
St-Malo, France
Strasbourg, France
Thionville, France
Toulon, France
+ 3 more on CT.gov